V ascular calcification is highly correlated with cardiovascular mortality and associated with hypertension. 1 Intima arterial calcification occurs in conjunction with atherosclerosis, and media calcification is usually present with systemic mineral imbalance caused by chronic renal disease. Although both types are pathologically distinct, there is an association between the molecular mechanism regulating vascular calcification in intima and media. We and others have described the involvement of receptor activator of nuclear factor κB ligand (RANKL) system with bone morphogenetic protein (BMP)-2 and BMP-4 axis in the development of intima and media calcification, respectively. 2,3 RANKL system consists of a triad of proteins: the membrane-bound RANK, its ligand RANKL, and the decoy receptor osteoprotegerin (OPG). This system occurs in immune system, 4,5 mammary glands development, 6 and has been studied extensively in bone metabolism, where osteoblasts express RANKL and OPG, which regulate osteoclast differentiation via RANK activation. 7, 8 The first insight about the importance of this system in vasculature came from studies in OPG −/− mice that show early onset of osteoporosis and severe media calcification. 9 The unopposed RANKL signaling present in OPG −/− mice was then related to the development of vascular calcification. Recently, we have described that RANKL plays an important role in aortic calcification under estrogen deficiency by acting on 2 important molecules of the calcification process: the inducer of calcification, BMP-2, and the inhibitor, matrix Gla protein. In addition, RANKL per se contributes to vascular calcification by increasing vascular smooth muscle cell Objective-Vascular calcification is accelerated by hypertension and also contributes to hypertension; however, it is an enigma why hypertension and vascular calcification are a vicious spiral. The present study elucidates the cross-talk between renin-angiotensin II system and receptor activator of nuclear factor-κB ligand (RANKL) system in vascular calcification. Approach and Results-Angiotensin (Ang) II (10 −7 mol/L) significantly increased calcium deposition as assessed by Alizarin Red staining, associated with a significant increase in the expression of RANKL, RANK, and bone-related genes, such as cbfa1 and msx2, in human aortic vascular smooth muscle cells. Infusion of Ang II (100 ng/kg per minute) in ovariectomized ApoE −/− mice under high-fat diet significantly increased the expression of RANKL system and calcification in vivo, whereas administration of Ang II receptor blocker (olmesartan, 3 mg/kg per day) decreased the calcification and bone markers' expression. In addition, male OPG −/− mice showed a significant increase in vascular calcification followed by Ang II infusion as compared with wild type. Conversely, RANKL significantly increased Ang II type 1 receptor and angiotensin II-converting enzyme expression in vascular smooth muscle cells via extracellular signal-regulated protein kinase phosphorylation. Conclusions-The present study demonstrated that Ang II significantly induced vascular calcification in vitro and in vivo through RANKL activation. In addition, RANKL activated renin-angiotensin II system, especially angiotensin II-converting enzyme and Ang II type 1 receptor. Cross-talk between renin-angiotensin II system and RANKL system might work as a vicious cycle to promote vascular calcification in atherosclerosis. Further studies to inhibit reninangiotensin II system and RANKL may provide new therapeutic options to prevent and regress vascular calcification. (Arterioscler Thromb Vasc Biol. 2013;33:1287-1296.) Key Words: angiotensin II ◼ calcification ◼ receptor activator of nuclear factor-κB ligand ◼ serum osteoprotegerin The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
(VSMC) dedifferentiation into osteoblast-like cell under osteogenic condition. 2 Although RANKL and RANK are highly detected in aortic atherosclerotic plaques and associated with calcification development, 2 the molecular mechanism that triggers RANKL system activation in vasculature remains to be elucidated.
On the basis of epidemiological evidence that vascular calcification is independently associated with hypertension, 1 in the present study, we focused on renin-angiotensin system (RAS) as the activator of RANKL system in vascular calcification. Here, we demonstrated the contribution of tissue RAS on the regulation of vascular RANKL system in 2 different models of vascular calcification, apolipoprotein (Apo) E −/− mice and OPG −/− mice.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Induction of Calcification by Ang II via RANKL Induction
Our previous report demonstrated that RANK, RANKL, and OPG were expressed in VSMC, and RANKL increased the calcium deposition and calcified nodule formation in human aortic VSMC under osteogenic-inducible culture condition. 2 Thus, in this study, we first examined the effect of Ang II on the calcification of human aortic VSMC. As shown in Figure 1A , Ang II (10 −7 mol/L) significantly increased the calcium deposition and calcified nodule formation, as assessed by Alizarin Red staining in human aortic VSMC under osteogenic-inducible culture condition during 2 weeks. Importantly, Ang II stimulation was more potent than RANKL (10 ng/mL; Figure 1B ), and costimulation with Ang II and RANKL further increased nodule formation ( Figure 1A and 1B). Ang II significantly increased the mRNA ( Figure 1C ) and protein expression of RANK and RANKL ( Figure 1D and 1E) in primary culture of VSMCs (mVSMCs) from wild-type (WT) mouse after 6-and 24-hour stimulation, respectively. Interestingly, Ang II also significantly increased the protein level of RANK and RANKL in OPG −/− mVSMCs after 24-hour stimulation ( Figure 1D and 1E ). Of note, RANK and RANKL protein levels were higher in OPG −/− mVSMCs as compared with WT mVSMCs (Figure 1D and 1E) . Consistently, in the presence of osteogenic-inducible medium, Ang II increased cbfa1 protein level in OPG −/− mVSMCs along with increase in RANKL levels after 2-day stimulation, whereas the addition of neutralizing anti-RANKL antibody (0.1 μg/mL) decreased cbfa1 expression induced by Ang II (Figure 1F and 1G ). From the measurement of OPG level in the supernatant of WT mVSMCs under RANKL and Ang II stimulation, RANKL significantly decreased OPG level, whereas Ang II showed no apparent effects during the 24-hour stimulation ( Figure 1H ). Interestingly, WT mVSMCs cultured in osteogenic medium showed a robust decrease in OPG level as compared with those cells in normal culture medium, and the effect of RANKL on the decrease in OPG level was also observed under the osteogenic condition ( Figure 1H ). The same result was observed in the human aortic VSMC ( Figure I in the online-only Data Supplement). To confirm the opposing effect of OPG on RANKL, WT mVSMCs cultured with RANKL showed an increase in cbfa1 expression level, which were significantly decreased when cells were cotreated with recombinant OPG (0.1 μg/mL); and a similar effect was observed with neutralizing anti-RANKL antibody (0.1 μg/mL; Figure 1I ). Taken together, the results demonstrated that Ang II induced the dedifferentiation of VSMC into osteoblastic phenotype via RANKL.
To test these findings in vivo, we examined the effects of Ang II in the ovariectomized (OVX) ApoE −/− mice. Our previous study described that OVX ApoE −/− mice showed the increased intima calcification, associated with a significant increased RANK and RANKL expression in media and intima layers of aorta under high-fat diet (HF) for 3 months. 2 In this study, we confirmed that HF/OVX group showed increased vascular calcification as compared with normal diet/OVX group (Figure 2A and 2B ). Infusion of a subpressor dose of Ang II (100 ng/kg per minute) during 3 months significantly increased the vascular calcification in this mouse model, as detected by Von Kossa staining (Figure 2A and 2B). Interestingly, calcium deposition could be detected both in the plaque area and in the media of aortic vessels (Figure 2A ). In addition, Ang II infusion significantly increased mRNA levels of RANK, RANKL, and OPG in the aorta ( Figure 2C ). The calcification inducer, BMP-2, and the osteogenic master transcription factor, cbfa1, as well as the calcification marker, osteopontin (OPN), were also upregulated in the aorta by Ang II infusion in HF group. However, Ang II did not affect the expression of RANK, RANKL, BMP-2, and osteopontin in the normal diet group ( Figure 1D ), suggesting that Ang IIinduced calcification in ApoE −/− mice might be dependent on HF-induced atherosclerosis.
Furthermore, we elucidated the role of Ang II in vascular calcification using the pharmacological and physiological blockade of Ang II. Treatment with an angiotensin II receptor blocker (ARB), olmesartan (3 mg/kg per day), significantly decreased the calcification area in HF/OVX ApoE −/− mice, as detected by Von Kossa staining (Figure 2A and 2B). ARB treatment also significantly decreased mRNA levels of RANK and RANKL in the aorta ( Figure 2C ), associated with the inhibition of BMP-2, cbfa1, and osteopontin expression ( Figure 2D ).
Role of OPG in Vascular Calcification
To further clarify the role of RANKL in Ang II-induced vascular calcification, we used male OPG −/− mice because the action of RANKL is inhibited in the presence of OPG. Indeed, RANKL activation in OPG −/− mice was reported to lead to the early onset of osteoporosis and media calcification. 9, 10 As shown in Figure 3 , although a few calcification spots were detected in the aorta of OPG −/− mice without Ang II, the marked increased calcification area was detected in OPG −/− mice after 1 month of Ang II infusion (100 ng/kg per minute; Figure 3A and 3B). OPG −/− mice showed significantly increased mRNA levels of RANK and RANKL in the aorta compared with WT group, and Ang II infusion further increased that expression ( Figure  3C ). Interestingly, Ang II increased OPG mRNA expression in WT group ( Figure 3C ). The calcification inducer, BMP-2, and the osteogenic master transcription factor, cbfa1, as well as the calcification marker osteopontin were also upregulated by Ang II infusion in OPG −/− group ( Figure 3D ). However, with that subpressor dose, Ang II did not affect the expression of those calcification-related genes in the WT group ( Figure 3D ). In addition, the expression levels of msx2 and cbfa1 were much higher in OPG −/− mVSMCs as compared with WT mVSMCs ( Figure 4A and 4B). In contrast, the levels of msx2 and cbfa1 were lower in mVSMCs from angiotensin II type 1 receptor (AT1R −/− )/OPG −/− mice as compared with OPG −/− mVSMCs even in the presence of osteogenic medium ( Figure  4A and 4B). Ang II stimulation is a well-known producer of reactive oxygen species (ROS) in VSMC, and cbfa1 and msx2 gene expression in aortic myofibroblasts and VSMC, respectively, have been reported to be upregulated by ROS generated by Nox and mitochondrial activity. 11, 12 We found that ROS production is accentuated in aortic tissues of OPG −/− compared with WT mice as detected by dihydroethidium staining of aortas collected after 1 month of Ang II infusion (100 ng/kg per minute; Figure 4C ). In accordance, we found that the ROS production may be related to the increase in calcification because the antioxidants pyrrolidine dithiocarbamate (10 mmol/L) and N-acetylcysteine (10 mmol/L) impaired the expression of msx2 and cbfa1 induced by Ang II stimulation in OPG −/− mVSMCs under osteogenic medium, as compared with WT mVSMCs ( Figure 4D and 4E ). Taken together with in vitro and in vivo findings, our data showed that Ang II induced vascular calcification through RANKL pathway and ROS production.
Circulating Levels of RANKL and OPG
As the high serum concentration of RANKL was reported to be related to acute myocardial infarction and ischemic cerebral vascular attacks, 13 we measured the level of serum RANKL and found that it was increased in HF/OVX group as compared with normal diet, and further increased after Ang II infusion ( Figure 5A ). In contrast, ARB administration significantly decreased serum RANKL level in the estrogen deficiency condition induced by OVX ( Figure 5A ).
To confirm these observations, we used OPG −/− mice because the measurement of RANKL is affected by the presence of OPG ( Figure IIA in the online-only Data Supplement). Similarly, in OPG −/− mice, OVX also significantly increased the serum RANKL level compared with sham operated female OPG −/− mice, and Ang II infusion further increased serum RANKL level ( Figure 5B ). Consistent with these data, serum RANKL level was significantly increased in OPG −/− mice as compared with WT mice, whereas RANKL level was significant lower in AT1R −/− /OPG −/− mice as compared with OPG −/− mice ( Figure  5C ). Finally, we measured serum OPG level. Although the estrogen deficiency was not enough to increase the serum OPG level in ApoE −/− mice, the infusion of a subpressor dose of Ang II (100 ng/kg per minute) significantly increased serum OPG level ( Figure 5D ). Serum OPG level would be likely increased by compensatory mechanisms under Ang II infusion. It is noteworthy that treatment with an ARB, olmesartan (3 mg/kg per day), further increased serum OPG level in HF/OVX group ( Figure 5D ). Because OPG is a decoy receptor for RANKL, OPG/RANKL ratio is reported to be a better diagnostic biomarker to determine the extent of vascular calcification. OPG/ RANKL ratio of ApoE −/− mice groups is shown in Figure 5E . 
Activation of RAS by RANKL Signaling
Finally, we examined the effects of RANKL on RAS components, especially AT1R and angiotensin II-converting enzyme (ACE) in vascular cells. Interestingly, AT1Ra mRNA level was higher in OPG −/− mVSMCs as compared with WT mVSMCs ( Figure 6A) . Similarly, the expression of ACE mRNA was also significantly increased in OPG −/− mVSMCs, whereas ACE mRNA level was lower in mVSMCs from AT1R −/− /OPG −/− mice as compared with OPG −/− mVSMCs ( Figure 6B ). Increase in ACE expression in OPG −/− mVSMCs is likely caused by the activation of RANKL because addition of neutralizing anti-RANKL antibody lowered ACE expression ( Figure 6B ). Accordingly, RANKL (10 ng/mL) significantly increased the protein level of AT1R ( Figure 6C and 6D) and ACE ( Figure   6E and 6F) both in WT and in OPG −/− mVSMCs. Because the expression of both genes of ACE and AT1R may be induced by upstream activation of MAPK/ERK pathway, 14 we focused on ERK phosphorylation. Expectedly, RANKL induced ERK phosphorylation as early as 5 minutes ( Figure 6G ), and the blockade of ERK phosphorylation by PD98059 significantly decreased ACE expression in OPG −/− VSMC ( Figure  6H ). NFκB pathway plays an important role in the RANKL signaling, and we confirmed that RANKL increased NFκB activity in WT, OPG −/− , and AT1R −/− /OPG −/− mVSMCs by luciferase reporter gene expression assay ( Figure 6I ). Interestingly, OPG −/− mVSMCs showed increased basal NFκB activity level as compared with WT and AT1R −/− /OPG −/− group, and Ang II was effective to increase NFκB activity only in that OPG −/− cells ( Figure 6I ). These results showed that RANKL signaling activated the local components of RAS, such as ACE and AT1R via MAPK/ERK pathway, and that the locally activated RAS may support RANKL-induced NFκB activation.
Discussion
Because vascular calcification is independently associated with older age, smoking, and hypertension in both men and women, 1 there is still little knowledge about the molecular mechanisms of vascular calcification. We have recently described that RANKL system contributes to vascular calcification by decreasing the calcification inhibitor, matrix Gla protein, in VSMC, and elevating BMP-2 expression by endothelial cells. RANKL also potentiated the VSMC dedifferentiation into osteoblast-like cells by inducing the expression of the master transcription factors: cbfa1 and msx2. 2 In the present study, we report that Ang II is the key factor for RANKL activation in vasculature, and that Ang II induces vascular calcification through RANKL pathway in vitro and in vivo. Our study further suggests that as RANKL upregulates ACE and AT1R, both RAS and RANKL system would induce vascular calcification synergistically.
Ang II is known to induce RANKL expression in mammary cells via JAK2/STAT5 pathway. 15 In this study, we also showed that Ang II increased RANKL mRNA level and RANK expression in VSMC ( Figure 1C-1E) , whereas the blockade of RANKL by neutralizing anti-RANKL antibody significantly inhibited Ang II-induced cbfa1 expression ( Figure 1F and 1G) . In contrast with other studies that show no direct effect of RANKL in the dedifferentiation of VSMC into osteoblast-like cells, 12, 16 we have reported the induction of cbfa1 expression under RANKL stimulation. 2 The discrepancy may be because of the addition of anti-OPG neutralizing antibody that by binding to the abundant endogenous OPG allowed the proper stimulation by RANKL in the VSMC and consequent induction of cbfa1 expression. 2 Of note, RANKL alone was not able to induce calcium deposition in VSMC, but enhanced the nodule formation under osteogenic condition, as shown in Figure 1A . Ang II also leads to NFκB activation via activation of RhoA and phosphorylation of NFκB at Ser536, which then activates the expression of inflammatory proteins. 17 We found that Ang II was effective to activate NFκB only in OPG −/− mVSMCs ( Figure 6I ), likely because of the high expression of AT1R in those cells ( Figure 6C and 6D). Therefore, both RANKL system and RAS may also contribute to the development of chronic inflammatory state and atherosclerosis. The contribution of immune cells as source of RANKL in the vasculature should not be ruled out, 18 and the involvement of RAS in the regulation of RANKL in T cells remains to be elucidated in vascular calcification.
The cross-talk of RANKL system and RAS for vascular calcification postulated in this study could also be observed in clinical situation, not only in our animal models. Hypertension is an independent and strong predictor of cardiovascular disease. 19 Interestingly, it is well known that vascular calcification is accelerated by hypertension and conversely also contributes to hypertension. It was an enigma why hypertension and vascular calcification form a vicious spiral-like caduceus, and the present study demonstrated that the cross-talk between RAS and RANKL plays a pivotal role, and that the blockade of Ang II by an ARB, olmesartan, significantly inhibited this vicious cycle because olmesartan inhibited vascular calcification and RANKL activation. Importantly, it is reported that the prognostic factors for progression of calcification is no use of ARBs in retrospective analysis. 20 Maahs et al 21 reported that ACE-I/ARB treatment of patients with diabetes mellitus with albuminuria is associated with lower odds of progression of coronary artery calcification. 21 Initiation of ARB treatment during the early stage might be effective to prevent vascular calcification, especially in postmenopausal women. The blockade of RANKL system has also been reported to be effective in this field. Denosumab, the full human RANKL antibody generally used to treat postmenopausal osteoporosis, 22 was reported to inhibit calcium deposition in preclinical studies in human RANKL knockin murine model, 23 although further clinical studies are necessary. Our present study also demonstrated the vicious spiral in circulating RANKL system. Serum level of free circulating RANKL was significantly increased in ApoE −/− HF/OVX, and administration of an ARB, olmesartan, decreased that level ( Figure 5A ). In accordance, AT1R −/− /OPG −/− mice showed lower level of serum RANKL as compared with OPG −/− mice ( Figure 5C ), suggesting that the blockade of angiotensin system activation might decrease the circulating-free RANKL. Serum OPG values are directly related to the severity of coronary heart disease and are elevated in older patients and those with diabetes mellitus, 24, 25 and correlate with abdominal aortic calcification. 26 Infusion of OPG in different animal models inhibited the incidence of calcification, 18, 27 and the inactivation of OPG in ApoE −/− mice accelerated the calcification progression. 28 Therefore, the increase in serum OPG levels found in patients may represent an insufficient compensatory mechanism to prevent further vascular damage. We found that Ang II significantly increased serum level of total OPG in both normal diet and HF-treated ApoE −/− mice ( Figure 4D) . As serum OPG level may be compensatory action and reflect the activation of RANKL system, the increase in OPG level may be beneficial. Increased serum OPG level by olmesartan may also contribute to inhibit vascular calcification and RANKL activation because the addition of recombinant mouse OPG led to no detection of serum RANKL in OPG −/− mice ( Figure IIA in the online-only Data Supplement). Of note, total OPG levels have been quantified by ELISA in this study because addition of recombinant RANKL showed no effect in OPG detection ( Figure IIB in the online-only Data Supplement). However, the binding of OPG to RANKL inhibited the detection of RANKL in the ELISA assay, thus only the free circulating RANKL in serum could be measured by this ELISA. Unexpectedly, increase in OPG level by olmesartan is intriguingly, and such significant increase of serum OPG might contribute to the prevention of vascular calcification. Estrogen deficiency induced by ovariectomy and HF would give the damage to the vessels of ApoE −/− mice, leading to the activation of local RAS 29,30 and RANKL system. 2 In this condition, the serum OPG level further increased by ARB treatment might successfully compensate RANKL activation, as shown by a significant decrease in the levels of free circulating RANKL and decrease in calcification incidence. However, the direct effect of ARB in decreasing RANKL levels cannot be ruled out. As a result, the ratio of OPG/RANKL was increased by Ang II infusion and was further increased by ARB treatment (Figure 5E ), suggesting that the ratio is not simply correlated to the vascular calcification status and may reflect the complex regulation of RANKL and OPG levels. On the basis of our results, we speculate that the free circulating serum RANKL level may be more predictive of the vascular calcification than OPG level or OPG/RANKL ratio.
The present study demonstrated that Ang II significantly induced vascular calcification in vitro and in vivo through RANKL activation. In addition, RANKL activated RAS, especially ACE and AT1R. Cross-talk between RAS and RANKL system might be a vicious cycle that promotes vascular calcification and inflammation in atherosclerosis. Further studies to inhibit RAS and RANKL may provide new therapeutic options to prevent and regress vascular calcification.
